Working… Menu
Trial record 1 of 1 for:    ALA-BCC-CT013
Previous Study | Return to List | Next Study

Study to Evaluate the Safety and Efficacy of BF-200 ALA (Ameluz®) and BF-RhodoLED® in the Treatment of Superficial Basal Cell Carcinoma (sBCC) With Photodynamic Therapy (PDT).

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT03573401
Recruitment Status : Recruiting
First Posted : June 29, 2018
Last Update Posted : September 1, 2020
Information provided by (Responsible Party):
Biofrontera Bioscience GmbH

No Study Results Posted on for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : July 2021
Estimated Study Completion Date : February 2026